These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 19362865)

  • 1. Updated results of bladder-sparing trimodality approach for invasive bladder cancer.
    Zapatero A; Martin de Vidales C; Arellano R; Bocardo G; Pérez M; Ríos P
    Urol Oncol; 2010; 28(4):368-74. PubMed ID: 19362865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term results of two prospective bladder-sparing trimodality approaches for invasive bladder cancer: neoadjuvant chemotherapy and concurrent radio-chemotherapy.
    Zapatero A; Martin De Vidales C; Arellano R; Ibañez Y; Bocardo G; Perez M; Rabadan M; García Vicente F; Cruz Conde JA; Olivier C
    Urology; 2012 Nov; 80(5):1056-62. PubMed ID: 22999456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conservative treatment of invasive bladder carcinoma by transurethral resection, protracted intravenous infusion chemotherapy, and hyperfractionated radiotherapy: long term results.
    Danesi DT; Arcangeli G; Cruciani E; Altavista P; Mecozzi A; Saracino B; Orefici F
    Cancer; 2004 Dec; 101(11):2540-8. PubMed ID: 15481058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Conservative treatment with chemotherapy and radiotherapy in bladder cancer invading the muscle: preliminary results of a prospective study].
    Zapatero A; Pinar B; Arellano R; López M; Marín A; Jiménez U; Pérez Torrubia A
    Arch Esp Urol; 1997 Jun; 50(5):448-54; discussion 454-6. PubMed ID: 9382586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiochemotherapy with cisplatin and 5-fluorouracil after transurethral surgery in patients with bladder cancer.
    Weiss C; Engehausen DG; Krause FS; Papadopoulos T; Dunst J; Sauer R; Rödel C
    Int J Radiat Oncol Biol Phys; 2007 Jul; 68(4):1072-80. PubMed ID: 17467193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy.
    George L; Bladou F; Bardou VJ; Gravis G; Tallet A; Alzieu C; Serment G; Salem N
    Urology; 2004 Sep; 64(3):488-93. PubMed ID: 15351577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can patient selection for bladder preservation be based on response to chemotherapy?
    Sternberg CN; Pansadoro V; Calabrò F; Schnetzer S; Giannarelli D; Emiliozzi P; De Paula F; Scarpone P; De Carli P; Pizzo M; Platania A; Amini M
    Cancer; 2003 Apr; 97(7):1644-52. PubMed ID: 12655521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bladder preservation in selected patients with muscle-invasive bladder cancer by complete transurethral resection of the bladder plus systemic chemotherapy: long-term follow-up of a phase 2 nonrandomized comparative trial with radical cystectomy.
    Solsona E; Climent MA; Iborra I; Collado A; Rubio J; Ricós JV; Casanova J; Calatrava A; Monrós JL
    Eur Urol; 2009 Apr; 55(4):911-9. PubMed ID: 18722046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Organ-sparing treatment in muscle-invasive bladder cancer.
    Dunst J; Diestelhorst A; Kühn R; Müller AC; Scholz HJ; Fornara P
    Strahlenther Onkol; 2005 Oct; 181(10):632-7. PubMed ID: 16220401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bladder-sparing, combined-modality approach for muscle-invasive bladder cancer: a multi-institutional, long-term experience.
    Perdonà S; Autorino R; Damiano R; De Sio M; Morrica B; Gallo L; Silvestro G; Farella A; De Placido S; Di Lorenzo G
    Cancer; 2008 Jan; 112(1):75-83. PubMed ID: 18008364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The results of concurrent chemo-radiotherapy for recurrence after treatment with bacillus Calmette-Guérin for non-muscle-invasive bladder cancer: is immediate cystectomy always necessary?
    Wo JY; Shipley WU; Dahl DM; Coen JJ; Heney NM; Kaufman DS; Zietman AL
    BJU Int; 2009 Jul; 104(2):179-83. PubMed ID: 19154448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience.
    Efstathiou JA; Spiegel DY; Shipley WU; Heney NM; Kaufman DS; Niemierko A; Coen JJ; Skowronski RY; Paly JJ; McGovern FJ; Zietman AL
    Eur Urol; 2012 Apr; 61(4):705-11. PubMed ID: 22101114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction cisplatin and fluorouracil-based chemotherapy followed by concurrent chemoradiation for muscle-invasive bladder cancer.
    Lin CC; Hsu CH; Cheng JC; Huang CY; Tsai YC; Hsu FM; Huang KH; Cheng AL; Pu YS
    Int J Radiat Oncol Biol Phys; 2009 Oct; 75(2):442-8. PubMed ID: 19307067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined modality treatment with bladder preservation for muscle invasive bladder cancer.
    Sabaa MA; El-Gamal OM; Abo-Elenen M; Khanam A
    Urol Oncol; 2010; 28(1):14-20. PubMed ID: 18818110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The fate of patients with locally advanced bladder cancer treated conservatively with neoadjuvant chemotherapy, extensive transurethral resection and radiotherapy: 10-year experience.
    Serretta V; Lo Greco G; Pavone C; Pavone-Macaluso M
    J Urol; 1998 Apr; 159(4):1187-91. PubMed ID: 9507829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy.
    Kaufman DS; Winter KA; Shipley WU; Heney NM; Wallace HJ; Toonkel LM; Zietman AL; Tanguay S; Sandler HM
    Urology; 2009 Apr; 73(4):833-7. PubMed ID: 19100600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bladder-sparing multimodality treatment of muscle-invasive bladder cancer: a five-year follow-up.
    Given RW; Parsons JT; McCarley D; Wajsman Z
    Urology; 1995 Oct; 46(4):499-504; discussion 504-5. PubMed ID: 7571218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective bladder preservation by combination treatment of invasive bladder cancer.
    Kaufman DS; Shipley WU; Griffin PP; Heney NM; Althausen AF; Efird JT
    N Engl J Med; 1993 Nov; 329(19):1377-82. PubMed ID: 8413433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proton beam therapy for invasive bladder cancer: a prospective study of bladder-preserving therapy with combined radiotherapy and intra-arterial chemotherapy.
    Hata M; Miyanaga N; Tokuuye K; Saida Y; Ohara K; Sugahara S; Kagei K; Igaki H; Hashimoto T; Hattori K; Shimazui T; Akaza H; Akine Y
    Int J Radiat Oncol Biol Phys; 2006 Apr; 64(5):1371-9. PubMed ID: 16580495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An organ-sparing treatment using combined intra-arterial chemotherapy and radiotherapy for muscle-invading bladder carcinoma.
    Tsukamoto S; Ishikawa S; Tsutsumi M; Nakajima K; Sugahara S
    Scand J Urol Nephrol; 2002; 36(5):339-43. PubMed ID: 12487737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.